Cytosorbents

Perfusfind S.L.

PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the recent data presentation entitled “Early CABG with Intraoperative Haemoadsorption in Patients on Ticagrelor:..

Perfusfind S.L.

Abstract Background The management of hemostasis in patients medicated with apixaban (Eliquis) undergoing emergency cardiac surgery is exceedingly difficult. The body’s natural elimination pathways for apixaban prove ineffective in emergency situations, and the impact of hemodialysis is limited. The application of Cytosorb® may attenuate the concentration of apixaban, thereby facilitating the..

Perfusfind S.L.

CytoSorb® Therapy extracorporeal blood purification is used: • in conditions where excessive levels of cytokines, bilirubin and/or myoglobin exist. • intraoperatively during cardio-pulmonary bypass (CPB) surgery for the removal of P2Y12-inhibitor ticagrelor and/or Factor-Xa-inhibitor rivaroxaban.  

Perfusfind S.L.

Abstract A dysregulated host response is a common feature in critically ill patients due to both infectious and non-infectious origins that can lead to life-threatening organ dysfunction, which is still the primary cause of death in intensive care units worldwide. In its course, pathologic, unregulated levels of inflammatory mediators are..

Perfusfind S.L.

This case reports on an 53-year-old female patient who was admitted to the hospital with an 8 day history of fever and chills, loose stools, vomiting, severe weakness, and reduced oral intake. [pdf-embedder url="https://perfusfind.com/wp-content/uploads/2023/12/CoM_12_2023_E_web_compressed.pdf"]  

Perfusfind S.L.

This case reports on a 41-years old male with no significant medical history who was admitted to the emergency room following 25% total body surface area (TBSA) deep partial thickness burns to his face, head and bilateral upper extremities. [pdf-embedder url="https://perfusfind.com/wp-content/uploads/2023/10/CoM_10_2023_E_web_compressed.pdf"]  

Perfusfind S.L.

This case reports on a 29-year-old male, who was transferred from a peripheral hospital with a diagnosis of COVID-19-associated lower respiratory tract infection, septic shock, and multiple organ dysfunction syndrome (MODS). [pdf-embedder url="https://perfusfind.com/wp-content/uploads/2023/10/CoM_09_2023_E_web_compressed.pdf"]  

Perfusfind S.L.

Abstract Introduction: Critically ill patients with inflammatory dysregulation and organ disfunction may benefit from blood purification, although the use of this technique has not been described in large case series. We evaluated clinical outcomes and survival in high-risk intensive care unit (ICU) patients who underwent extracorporeal blood purification. Methods: 359 consecutive ICU..

Perfusfind S.L.

Abstract PRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) --   (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, highlights the growing momentum of ex vivo organ perfusion in organ transplantation and the vital role CytoSorb® and..

Perfusfind S.L.

Abstract Introduction Cytokine adsorption using the CytoSorb® adsorber has been proposed in various clinical settings including sepsis, ARDS, hyperinflammatory syndromes, cardiac surgery or recovery after cardiac arrest. The aim of this analysis is to provide evidence for the efficacy of the CytoSorb® adsorber with regard to mortality in various settings...